Atrial fibrillation market to decline to $10.5 billion across 8MM in 2032

The atrial fibrillation (AF) market across the eight major markets (8MM) is forecast to decline at a negative compound annual growth rate (CAGR) of 3.2% from $14.5 billion in 2022 to $10.5 billion in 2032, primarily driven by generic sales erosion of the leading novel oral anticoagulants ((NOACs).

According to pharma analytics firm GlobalData’s latest report, “Atrial Fibrillation: Eight Market Drug Forecast and Market Analysis- Update,” the market decline will be mainly driven by a drop in sales of the four leading NOACs - Boehringer Ingelheim’s Pradaxa (dabigatran), Bayer’s (BAYN: DE) Xarelto (rivaroxaban), Bristol Myers Squibb’s (NYSE: BMY) Eliquis (apixaban), and Daiichi Sankyo’s (TYO: 4568) Savaysa (edoxaban).

Dr Shireen Mohammad, senior cardiovascular and metabolic analyst at GlobalData, commented: “Nevertheless, part of these losses will be offset by the introduction and uptake of novel FXI/FXIa inhibitors, which are expected to launch across the 8MM throughout the forecast period 2022-32. In addition, the calcium channel blocker etripamil is anticipated to launch during the forecast period.”